Latest Period
Q1 2026
Security Snapshot
Biodexa Pharmaceuticals Plc - American Depositary Shares, each representing four hundred ordinary shares (BDRX) Institutional Ownership
CUSIP: 59564R880
13F Institutional Holders and Ownership History from Q3 2025 to Q1 2026
Institutions Reporting
7
Shares (Excl. Options)
368,950
Price
$0.62
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / American Depositary Shares, each representing four hundred ordinary shares
- Symbol
- BDRX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 368,950
- Total 13F value
- $227,974
- Portfolio coverage rank
- 0%
- Share change
- +63,677
- Value change
- +$21,726
- Number of holders
- 7
- Shares outstanding
- 1,881,632
- SEC-reported price per share
- $0.62
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BDRX - Biodexa Pharmaceuticals Plc - American Depositary Shares, each representing four hundred ordinary shares is tracked under CUSIP 59564R880.
- 7 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 8 to 7 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $692,946 to $227,974.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 7 institutions filings for Q1 2026.
Security key
59564R880
Latest holder period
Q1 2026
13F holders
7
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
BDRX full holder history
Biodexa Pharmaceuticals Plc SEC filings
Biodexa Pharmaceuticals Plc company facts
Biodexa Pharmaceuticals Plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 59564R880:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
BDRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| SABBY MANAGEMENT, LLC | 9.9% | $493,974 | 217,600 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | |||
| ARMISTICE CAPITAL, LLC | 10% | 0% | $116,150 | -$59,026 | 187,975 | -34% | Armistice Capital, LLC | 31 Mar 2026 |
As of 31 Mar 2026, 7 institutional investors reported holding 368,950 shares of Biodexa Pharmaceuticals Plc - American Depositary Shares, each representing four hundred ordinary shares (BDRX). This represents 20% of the company’s total 1,881,632 outstanding shares.
13F concentration
Top 9 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
20%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SABBY MANAGEMENT, LLC | 14% | 257,472 | +35% | 2.8% | $159,092 |
| ARMISTICE CAPITAL, LLC | 5.2% | 97,521 | -2.5% | 0% | $60,258 |
| GAMMA Investing LLC | 0.73% | 13,780 | +675% | 0% | $8,515 |
| UBS Group AG | 0.01% | 127 | -94% | 0% | $78 |
| Hilton Head Capital Partners, LLC | 0% | 30 | 0% | 0% | $19 |
| RHUMBLINE ADVISERS | 0% | 19 | -21% | 0% | $11 |
| Caitong International Asset Management Co., Ltd | 0% | 1 | 0% | $1 | |
| HRT FINANCIAL LP | 0% | 0 | -100% | $0 | |
| SBI Securities Co., Ltd. | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Latest
Q1 2026
Rows shown
1-3 of 3